EyeGate gets USPTO notice of allowance for proprietary dexamethasone phosphate formulation
The patent covers a method of treating eye conditions using EyeGate’s proprietary Dexamethasone Phosphate pharmaceutical formulation delivered by ocular iontophoresis. The patent is not limited to any particular
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.